Awards/ Honors details: 

• Indian Medical Association - Association of Medical Specialties Dr. Eapen Samuel award for the best clinical research paper in Kerala state for the year 2016-2017.

Publications of the last 5 years in relevant areas: 

• Moni Merlin, Sidharthan Neeraj, Sudhir Sangita, Prabhu Binny  et al., A quality improvement initiative to improve the appropriateness of candidemia management by the implementation of a comprehensive candidemia care bundle at a tertiary care hospital in South India. Medicine:  Volume 101 - Issue 13. 2022
• M. Malavika, S. Sanju, M.R. Poorna, Veeraraghavan Vishnu Priya, Neeraj Sidharthan, Praveen Varma. Role of myeloid derived suppressor cells in sepsis. International Immunopharmacology 104 (2022) 108452.
• Dana Merin, Akshaya Krishna, Sreelekshmi Jayakumar, A Mahima, K N Anila and Neeraj Sidharthan. Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study. J Oncol Pharm Practice. 2022. 

Details of ongoing/completed projects:

• Principal Investigator: A prospective, multi-centre, phase IV clinical trial to assess the safety and efficacy of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia and relapsed and refractory mantle cell lymphoma in AstraZeneca Pharmaceuticals India Pvt Ltd
• Principal Investiqator: A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB12 (proposed eculizumab biosimilar) and Soliris® in Subjects with Paroxysmal Nocturnal Haemoglobinuria in Samsung Bioepis Co., Ltd, Republic of Korea
• Principal Investigator:    A prospective, multicenter, randomized, double blind study to compare the efficacy andsafety of ENZ110 (similar biologic of Romiplostim) versus innovator Romiplostim in patients with chronic immune thrombocytopenia (ITP) in Alkem Laboratories Ltd, india
• Principal Investigator: Safety and efficacy study of AZADINE® (Azacitidine) in treatment of myelodysplastic syndrome in Indian patient in IntasPahrmaceuticals Ltd, India
• Principal Investigator:Phase IV multi-center, prospective, interventional, post-marketing study in Hemophilia B Patients in India receiving Rixubis as on-demand or prophylaxis under standard clinical practice in Baxalta Innovations GMBH, Austria
• Principal Investigator: Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India in Novo Nordisk, Denmark